Abstract：Objective: To explore the efficacy of protamine recombinant human insulin mix 40/60 (referred to as Gansulin 40/60) in treating elderly patients with type 2 diabetes (T2DM) and its impact on prognosis. Methods: A total of 106 elderly T2DM patients admitted to Western Theater General Hospital between December 2022 and December 2023 were randomly divided into a control group (n=53) and a treatment group (n=53). The control group received standard dual antidiabetic therapy (metformin + dapagliflozin), while the treatment group was given Gansulin 40/60 subcutaneous injections. After 12 weeks, efficacy and safety were evaluated, and pre- and post-treatment glycemic indicators, body mass index (BMI), β-cell function, and serum levels of monocyte chemoattractant protein-1 (MCP-1), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) were measured. The prognosis of both groups was tracked for 6 months. Results: The overall effective rate in the treatment group was 90.57%, higher than that in the control group (71.70%) (P<0.05). After treatment, the treatment group showed lower fasting plasma glucose (FPG), 2-hour postprandial glucose (2hPG), glycosylated hemoglobin (HbA1c), homeostasis model assessment of insulin resistance (HOMA-IR), and serum MCP-1, hs-CRP, and IL-6 levels, and higher β-cell function index (HOMA-β) compared to the control group (P<0.05). The overall incidence of adverse reactions in the treatment group (3.77%) was not significantly different from that in the control group (7.55%) (P>0.05). There was no significant difference in the incidence of microvascular complications between the two groups over the 6-month follow-up period (P>0.05). Conclusion: Subcutaneous injection of Gansulin 40/60 in elderly T2DM patients is safe and effective, lowering blood glucose levels, promoting β-cell function recovery, and reducing inflammation, though it does not significantly improve short-term prognosis.
肖瑶, 潘尹红, 马利红, 秦杨. 精蛋白重组人胰岛素混合注射液40/60治疗老年2型糖尿病的疗效及对患者预后的影响[J]. 河北医学, 2024, 30(10): 1733-1738.
XIAO Yao, PAN Yinhong, MA Lihong, et al. Efficacy of Protamine Recombinant Human Insulin Mix 40/60 in Treating Elderly Patients with Type 2 Diabetes and Its Impact on Prognosis. HeBei Med, 2024, 30(10): 1733-1738.
[1] 刘福君,常李李,王为兰,等.肝脏胰岛素抵抗与2型糖尿病[J].中国医学科学院学报,2022,44(4):699-708. [2] 薛淇丹,刘梅,陈钦达.2型糖尿病患者使用预混胰岛素血糖控制不佳转换为德谷门冬双胰岛素治疗1例[J].中华糖尿病杂志,2024,16(1):46-48. [3] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华内分泌代谢杂志,2021,37(4):311-398. [4] 中国微循环学会糖尿病与微循环专业委员会,中华医学会内分泌学分会基层内分泌代谢病学组,孙子林.基层糖尿病微血管疾病筛查与防治专家共识(2024)[J].中国全科医学,2024,27(32):3969-3986. [5] Ali MK,Pearson-Stuttard J,Selvin E,et al.Interpreting global trends in type 2 diabetes complications and mortality[J].Diabetologia,2022,65(1):3-13. [6] 李丽莉,冯翠娟,冯克娜.二甲双呱治疗血糖控制不佳的T2DM联合达格列净对机体糖脂指标、内脏脂肪、慢性炎症刺激的调节效应[J].河北医科大学学报,2022,43(12):1384-1389. [7] 《2型糖尿病短期胰岛素强化治疗专家共识》编写委员会.2型糖尿病短期胰岛素强化治疗专家共识(2021年版)[J].国际内分泌代谢杂志,2022,42(1):67-77. [8] Hao S,Umpierrez GE,Daley T,et al.Intervention with therapeutic agents,understanding the path to remission in type 2 diabetes: part 1[J].Endocrinol Metab Clin North Am,2023,52(1):27-38. [9] Rohm TV,Meier DT,Olefsky JM,et al.Inflammation in obesity,diabetes,and related disorders[J].Immunity,2022,55(1):31-55. [10] 黄慧,王军,李光来,等.甘舒霖40R、诺和锐30治疗老年2型糖尿病患者控糖效果比较及对预后影响分析[J].临床军医杂志,2023,51(4):378-380,383. [11] Tommerdahl KL,Shapiro ALB,Nehus EJ,et al.Early microvascular complications in type 1 and type 2 diabetes: recent developments and updates[J].Pediatr Nephrol,2022,37(1):79-93.
2024, Vol. 30 
冀公网安备13080202000677号